[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hodgkin-s-granuloma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":309,"states":324},"Hodgkin's Granuloma",90,78,[8,16,22,29,35,41,47,54,60,67,73,79,85,91,97,103,109,114,120,126,132,138,144,150,156,162,168,174,180,186,192,198,203,209,215,220,226,232,238,244,251,257,263,269,275,281,287,292,297,303],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03618550","Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:16:44.178623Z","2026-07-19T19:36:05.115156Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05355051","A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed\u002FRefractory Hodgkin's Lymphoma",[12],"2026-08-26T02:18:39.640967Z","2026-07-05T05:32:16.798775Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT02917083","CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)",[26],"Phase 1","2026-08-26T02:17:13.277148Z","2026-05-29T15:36:40.172598Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06377566","A Study of BV-AVD in People With Bulky Hodgkin Lymphoma",[12],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.352411Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07551583","Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL",[12],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.322827Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06915246","A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma",[12],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:29.077122Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT05675410","A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab",[51],"Phase 3","2026-08-26T02:16:01.910993Z","2026-05-05T02:43:28.845138Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04871607","Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma",[12],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:28.515123Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT06090864","ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells",[64],"Phase 1\u002FPhase 2","2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.510158Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07002216","BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.318838Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05272384","Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma",[26],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.137336Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07188090","Mozobil for Autologous Hematopoietic Stem Cell Transplantation",[12],"2026-08-26T02:16:04.914942Z","2026-05-05T02:43:28.971071Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06137144","AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.",[64],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.704937Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT01555892","Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE",[26],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.315377Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT04664179","EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma",[26],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.322391Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial",[12],"2026-08-26T02:15:04.877798Z","2026-07-19T19:36:05.038415Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":83,"content_modified":113},"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)",[51],"2026-07-05T05:32:16.764159Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT04902443","Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV",[26],"2026-08-26T02:17:27.435233Z","2026-06-18T12:24:02.872345Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer",[12],"2026-08-26T02:15:09.079045Z","2026-05-13T02:55:06.730274Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT07451054","CD45BE-HSPC + CART-45 Cells",[26],"2026-08-26T02:16:39.977107Z","2026-05-13T02:55:06.706937Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[64],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06484920","A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:29.397408Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT07283822","Amping up With PemJAK",[12],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:29.349629Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT02508038","Alpha\u002FBeta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors",[26],"2026-08-26T02:17:26.640202Z","2026-05-05T02:43:29.192915Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT05031897","Two Step Haplo With Radiation Conditioning",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.158573Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT02727803","Personalized NK Cell Therapy in CBT",[12],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:29.030294Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT05554068","Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients",[12],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.020712Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT05798897","Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed\u002FRefractory Lymphoma",[26],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:29.017826Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT06008808","Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation",[26],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:28.872786Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06680661","ABBA CORD: dCBT w\u002F Abatacept for aGVHD Prophylaxis",[12],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:28.824003Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT04099966","AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha\u002FBeta T Cell and CD19+ B Cell Depletion",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:28.713058Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":95,"content_modified":202},"NCT07444632","Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed\u002FRefractory Lymphoid Malignancies",[26],"2026-05-05T02:43:28.704804Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[64],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT04491370","Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",[64],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:28.622855Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":136,"content_modified":219},"NCT05800210","Alpha\u002FBeta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases",[12],"2026-05-05T02:43:28.348250Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT06028828","Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation",[12],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:28.300701Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT05857969","Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling",[26],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.220097Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT05544968","Anti-CD30 biAb-AATC in Patients With Relapsed\u002FRefractory CD30 Positive Hematopoietic Malignancies",[26],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.997953Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[64],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":249,"content_modified":250},"NCT06398457","Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",[248],"Early Phase 1","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:27.839395Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT05476770","Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies",[26],"2026-08-26T02:17:16.980188Z","2026-05-05T02:43:27.744798Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":261,"content_modified":262},"NCT06150664","A Phase 1 of CTX-8371 in Patients With Advanced Malignancies",[26],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:27.515153Z",{"nct_id":264,"title":265,"phases":266,"status":13,"updated_at":267,"content_modified":268},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[12],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.479357Z",{"nct_id":270,"title":271,"phases":272,"status":13,"updated_at":273,"content_modified":274},"NCT06176690","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas",[26],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:27.308921Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT04644016","Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders",[12],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:27.256850Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:26.753431Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":166,"content_modified":291},"NCT05038150","Study of SGN1 in Patients With Advanced Solid Tumor",[64],"2026-05-05T02:35:31.902772Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":52,"content_modified":296},"NCT06059391","CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant",[12],"2026-05-05T02:35:31.868600Z",{"nct_id":298,"title":299,"phases":300,"status":13,"updated_at":301,"content_modified":302},"NCT06926595","Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention",[12],"2026-08-26T02:19:22.562392Z","2026-05-05T02:35:31.707594Z",{"nct_id":304,"title":305,"phases":306,"status":13,"updated_at":307,"content_modified":308},"NCT05327023","Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies",[64],"2026-08-26T02:16:15.345907Z","2026-05-05T02:35:31.707199Z",[310,314,318,321],{"biomarker":311,"count":312,"slug":313},"HLA Complex",6,"hla-complex",{"biomarker":315,"count":316,"slug":317},"BCR\u002FABL1 Fusion Gene",4,"bcr-abl1-fusion-gene",{"biomarker":319,"count":316,"slug":320},"CD70 Antigen","cd70-antigen",{"biomarker":322,"count":316,"slug":323},"TNFRSF8 Gene","tnfrsf8-gene",[325,329,333,337,341,345,349,352,355,359,363,367,370,374,377,380,384,387,390,393,396,399,402,405],{"state":326,"count":327,"slug":328},"Texas",24,"texas",{"state":330,"count":331,"slug":332},"California",22,"california",{"state":334,"count":335,"slug":336},"New York",20,"new-york",{"state":338,"count":339,"slug":340},"Florida",18,"florida",{"state":342,"count":343,"slug":344},"Massachusetts",14,"massachusetts",{"state":346,"count":347,"slug":348},"Georgia",13,"georgia",{"state":350,"count":347,"slug":351},"Maryland","maryland",{"state":353,"count":347,"slug":354},"Pennsylvania","pennsylvania",{"state":356,"count":357,"slug":358},"Tennessee",12,"tennessee",{"state":360,"count":361,"slug":362},"Wisconsin",11,"wisconsin",{"state":364,"count":365,"slug":366},"Michigan",9,"michigan",{"state":368,"count":365,"slug":369},"North Carolina","north-carolina",{"state":371,"count":372,"slug":373},"Illinois",8,"illinois",{"state":375,"count":372,"slug":376},"Ohio","ohio",{"state":378,"count":372,"slug":379},"Washington","washington",{"state":381,"count":382,"slug":383},"Arizona",7,"arizona",{"state":385,"count":382,"slug":386},"Missouri","missouri",{"state":388,"count":382,"slug":389},"Oregon","oregon",{"state":391,"count":312,"slug":392},"Colorado","colorado",{"state":394,"count":312,"slug":395},"Indiana","indiana",{"state":397,"count":312,"slug":398},"Minnesota","minnesota",{"state":400,"count":312,"slug":401},"New Jersey","new-jersey",{"state":403,"count":312,"slug":404},"Virginia","virginia",{"state":406,"count":407,"slug":408},"Alabama",5,"alabama"]